デジタルバイオマーカー市場の規模、シェア、動向分析レポート：タイプ別（ウェアラブル、モバイルベースアプリケーション、センサー）、臨床行為別、治療領域別、最終用途別、地域別、セグメント別予測、2022年～2030年

デジタルバイオマーカー市場の成長と動向

Grand View Research, Inc.の最新レポートによると、デジタルバイオマーカーの世界市場規模は、予測期間中に21.9%のCAGRを記録し、2030年までに139億6,616万米ドルに達すると予測されています。最近の進歩や遠隔技術の受け入れが進んでいることから、デジタルバイオマーカーの市場は予測期間を通じて拡大すると予想されています。デジタルバイオマーカー市場の最大セグメントを構成する遠隔データ収集技術の開拓は、ウェアラブル技術およびモバイル技術の向上により推進されています。さらに、この市場セグメントは、インターネットの利用が拡大していることによって、さらに促進されています。

特に、音声デジタルバイオマーカーは最近登場し、大きなビジネス展開の可能性を秘めています。音声記録や携帯電話、ウェアラブル端末などの患者所有の技術を通じて、簡単にデータを収集することができます。音声バイオマーカーは、ヘルスケアシステムの負担を軽減し、身体的または精神的疾患の早期介入と事前特定を強化することで患者の予後を改善する可能性があり、予測期間中の市場拡大を後押しします。

さらに、市場のプレゼンスを獲得し、予測期間中に収益市場シェアをさらに高めるために、プレイヤーは音声デジタルバイオマーカーの探索も始めています。例えば、2021年10月、Sonde health社は、音声対応メンタルフィットネスモニタリング技術プラットフォームを発表しました。

さらに、慢性疾患や神経変性疾患の有病率の上昇や、これらの疾患をうまくコントロールするための薬剤開発の強化の必要性が高まっていることから、市場は予測期間中に大幅に拡大すると予想されます。デジタルバイオマーカーは、従来の臨床試験プロセスとは異なり、新薬の開発を加速させることができます。

分散型臨床試験プラットフォームのプロバイダーの1つであるMed ableの調査によると、すべての臨床試験の85.0%が何らかの遅延を経験しており、遅延による経済的影響は1日あたり60万米ドルから800万米ドルに上ります。分散型臨床試験では、第2相試験の時間を最大で1～3カ月短縮できると言われています。その結果、医薬品メーカーはDCTのデジタルバイオマーカーに資金を投入しており、市場拡大を促進すると予想されます。例えば、アストラゼネカは2022年3月、遠隔デジタルバイオマーカーに基づく分散型臨床試験を提供する英国のHUMA社に3300万米ドルを投資したと表明しています。この提携により、DCTの採用を加速させる。

先見の明のある市場参入企業は、将来の成功に必要な幅広い技術力とサービスを活用し、デジタル・バイオマーカーの世界市場における自社のポジションを強化するために、決定を拡大し、典型的なサプライヤーの枠を越えて動いています。これらの企業は、製品の上市、ジョイントベンチャー、M&Aなど、さまざまな戦略を採用しています。例えば、2022年4月、ファイザーは、人工知能を使用して患者の咳の声を使用して呼吸器系問題の重症度を測定・判断するアプリを作成したオーストラリアを拠点とするスタートアップ企業、ResApp社を買収しました。

デジタルバイオマーカー市場レポートハイライト

2021年の治療分野別セグメントでは、心血管・代謝疾患（CVMD）が20.0％以上の高い収益シェアを占めており、世界中の患者集団における心血管疾患の有病率が上昇していることから、今後も大きな主要存在であり続けると予想されます。一方、COVID-19や新たな新技術により、予測期間中、呼吸器系疾患の市場収益シェアは最も速い速度で拡大すると予測される

臨床疾患や日常生活のために意味される診断モニタリングの使用が増加しているため、診断用デジタルバイオマーカーは2021年に臨床診療セグメントで最大の収益シェアを占めました。さらに、予測期間中、モニタリング用デジタルバイオマーカーが最も速い収益成長を遂げると予想される

ウェアラブルは、最先端のウェアラブルスマートウォッチなどの新製品の発売により、2021年のデジタルバイオマーカーのタイプ別セグメントで39.0%以上の収益シェアとなっています。スマートフォンが世界中で広く利用されるようになった結果、予測期間中、モバイルベースのアプリケーションの収益シェアが最も速い速度で成長すると予測されます。また、新技術やセンサーの利用が増加し、予測期間中に激しい競合が発生することが予想されます。

ヘルスケア企業は、適応症の増加や費用対効果の高い臨床試験および製品分析戦略への要求の結果として、2021年の最終用途カテゴリ内で最大の50.0％以上の市場シェアを占めています。

北米は、確立された高度なヘルスケアインフラと研究開発活動への多額の支出の結果、2021年に市場を独占し、総収入の59.0%以上のシェアを獲得しました。さらに、予測期間中は欧州が最も速い成長率を示すだろう

提携、買収、合併、製品の発売を行うことで、主要企業も市場の拡大に貢献しています。例えば、2021年にMed ableは、デジタルバイオマーカー事業のAural Analyticsと提携し、遠くのスピーチパターンを測定し、健康状態や衰えの段階を監視している

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
• 調査手法
• 情報調達
  • 購入したデータベース：
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析（モデル1）
    • アプローチ1：コモディティフローアプローチ
• 二次情報一覧
• 一次情報のリスト
• 報告の目的

第2章 エグゼクティブサマリー

• 市場の見通し
• デジタルバイオマーカー市場の概要、2021年

第3章 デジタルバイオマーカー市場の変数、動向、範囲

• 市場系列の見通し
  • 親市場の見通し
  • アンシラリー市場の見通し
• 浸透と成長の見通しのマッピング
• デジタルバイオマーカー市場力学
  • 市場促進要因分析
    • 最近のイノベーションとリモート技術の人気の高まり
    • スマートフォンの使用の増加と新しいウェアラブルの出現
    • 治療領域の拡大
    • 分散型臨床試験への投資の増加
  • 市場抑制要因分析
    • データプライバシーに関する懸念
    • 新興経済学における意識の欠如と熟練した専門家の不足
• デジタルバイオマーカー市場分析ツール：ポーターのファイブフォース分析
  • サプライヤーの力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係
• PESTEL分析
  • 政治と法律の情勢
  • 社会情勢
  • テクノロジー情勢
  • 環境分析
• 規制の枠組み
• 技術概要
• 価格分析
• COVID-19影響分析
  • 現在および将来の影響分析
  • COVID-19が市場関係者に与える影響

第4章 競合情勢

• 市場参加の分類
• 公開会社
  • 会社の市況分析
  • 相乗効果分析：主要取引と戦略的提携
• 市場プレーヤーの詳細なリスト

第5章 デジタルバイオマーカー市場：セグメント分析、タイプ別、2017年から2030年（百万米ドル）

• タイプ変動分析、2021 &2030
  • ウェアラブル
  • モバイルベースのアプリケーション
  • センサー
  • その他

第6章 デジタルバイオマーカー市場：セグメント分析、臨床実践別、2017年から2030年（百万米ドル）

• 2021年と2030年の臨床実践変動分析
  • 診断用デジタルバイオマーカー
  • デジタルバイオマーカーのモニタリング
  • 予測および予後のデジタルバイオマーカー
  • その他

第7章 デジタルバイオマーカー市場：セグメント分析、治療領域別、2017年から2030年（百万米ドル）

• 治療領域の変動分析、2021年および2030年
  • 心血管および代謝障害（CVMD）
  • 呼吸器疾患
  • 精神障害
  • 睡眠と運動の病気
  • 神経学的障害
  • 筋骨格系疾患
  • その他

第8章 デジタルバイオマーカー市場：セグメント分析、最終用途別、2017年から2030年（百万米ドル）

• 最終用途変動分析、2021年および2030年
  • ヘルスケア企業
  • ヘルスケア提供者
  • 支払人
  • その他

第9章 デジタルバイオマーカー市場：2017年から2030年までのタイプ、臨床診療、治療分野、および最終用途別の地域市場分析（100万米ドル）

• 市場規模、予測、量、トレンド分析、2017年から2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • オランダ
  • イタリア
  • スイス
• アジア太平洋地域
  • 日本
  • 中国
  • オーストラリア
  • インド
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
• MEA
  • 南アフリカ
  • イスラエル

第10章 企業プロファイル

• ActiGraph LLC
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• AliveCor Inc
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Koneksa
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Amgen Inc.
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Biogen Inc.
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Altoida Inc
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• IXICO plc
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Adherium Limited
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Empatica Inc
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• Huma
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• VivoSense
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• ResApp（Pfizer）
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ

List of Tables

• Table 1. List of secondary sources
• Table 2. List of key companies
• Table 3. North America Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
• Table 4. North America Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 5. North America Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 6. North America Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 7. North America Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 8. U.S. Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 9. U.S. Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 10. U.S. Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 11. U.S. Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 12. Canada Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 13. Canada Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 14. Canada Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 15. Canada Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 16. Europe Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
• Table 17. Europe Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 18. Europe Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 19. Europe Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 20. Europe Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 21. U.K. Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 22. U.K. Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 23. U.K. Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 24. U.K. Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 25. Germany Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 26. Germany Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 27. Germany Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 28. Germany Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 29. Netherlands Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 30. Netherlands Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 31. Netherlands Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 32. Netherlands Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 33. Italy Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 34. Italy Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 35. Italy Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 36. Italy Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 37. Switzerland Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 38. Switzerland Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 39. Switzerland Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 40. Switzerland Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 41. Asia Pacific Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
• Table 42. Asia Pacific Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 43. Asia Pacific Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 44. Asia Pacific Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 45. Asia Pacific Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 46. China Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 47. China Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 48. China Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 49. China Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 50. Japan Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 51. Japan Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 52. Japan Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 53. Japan Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 54. India Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 55. India Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 56. India Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 57. India Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 58. Australia Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 59. Australia Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 60. Australia Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 61. Australia Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 62. South Korea Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 63. South Korea Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 64. South Korea Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 65. South Korea Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 66. LATAM Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
• Table 67. LATAM Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 68. LATAM Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 69. LATAM Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 70. LATAM Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 71. Brazil Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 72. Brazil Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 73. Brazil Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 74. Brazil Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 75. Mexico Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 76. Mexico Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 77. Mexico Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 78. Mexico Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 79. MEA Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
• Table 80. MEA Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 81. MEA Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 82. MEA Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 83. MEA Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 84. South Africa Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 85. South Africa Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 86. South Africa Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 87. South Africa Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 88. Israel Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 89. Israel Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 90. Israel Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 91. Israel Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
• Table 92. Global Digital Biomarkers market, by region, 2017 - 2030 (USD Million)
• Table 93. Global Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
• Table 94. Global Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
• Table 95. Global Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
• Table 96. Global Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD Modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Commodity flow analysis
• Fig. 10 Segment-Based Penetration Model
• Fig. 11 Market summary (2021, Million)
• Fig. 12 Penetration & growth prospect mapping
• Fig. 13 Market variable analysis
• Fig. 14 Market driver relevance analysis (Current & future impact)
• Fig. 15 Market restraint relevance analysis (Current & future impact)
• Fig. 16 Digital Biomarkers Market: By Type Movement Analysis, 2021 & 2030
• Fig. 17 Wearable Market, 2017 - 2030 (Million)
• Fig. 18 Mobile based Applications Market, 2017 - 2030 (Million)
• Fig. 19 Sensors Market, 2017 - 2030 (Million)
• Fig. 20 Others Market, 2017 - 2030 (Million)
• Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis, 2021 & 2030
• Fig. 22 Diagnostic digital biomarkers market, 2017 - 2030 (Million)
• Fig. 23 Monitoring digital biomarkers market, 2017 - 2030 (Million)
• Fig. 24 Predictive and Prognostic digital biomarkers market, 2017 - 2030 (Million)
• Fig. 25 Others digital biomarker market, 2017 - 2030 (Million)
• Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis, 2021 & 2030
• Fig. 27 Cardiovascular and metabolic disorders (CVMD) market, 2017 - 2030 (Million)
• Fig. 28 Respiratory disorders market, 2017 - 2030 (Million)
• Fig. 29 Psychiatric disorders market, 2017 - 2030 (Million)
• Fig. 30 Sleep & movement disease market, 2017 - 2030 (Million)
• Fig. 31 Neurological disorders market, 2017 - 2030 (Million)
• Fig. 32 Musculoskeletal disorders market, 2017 - 2030 (Million)
• Fig. 33 Others market, 2017 - 2030 (Million)
• Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis, 2021 & 2030
• Fig. 35 Healthcare companies market, 2017 - 2030 (Million)
• Fig. 36 Healthcare Providers market, 2017 - 2030 (Million)
• Fig. 37 Payers market, 2017 - 2030 (Million)
• Fig. 38 Others market, 2017 - 2030 (Million)
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 Regional outlook, 2021 & 2030
• Fig. 41 North America Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 42 U.S. Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 43 Canada Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 44 Europe Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 45 U.K. Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 46 Germany Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 47 Netherlands Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 48 Italy Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 49 Switzerland Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 50 Asia Pacific Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 51 Japan Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 52 China Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 53 India Digital Biomarkers Market, 2017- 2030 (Million)
• Fig. 54 South Korea Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 55 Australia Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 56 Latin America Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 57 Brazil Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 58 Mexico Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 59 MEA Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 60 South Africa Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 61 Israel Digital Biomarkers Market, 2017 - 2030 (Million)
• Fig. 62 Market Participation Categorization
• Fig. 63 Company market position analysis 

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9% during the forecast period, according to a new report by Grand View Research, Inc. Due to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.

Vocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market's expansion during the forecast period.

Furthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.

Additionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.

According to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies. As a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.

Forward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company's position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success. These companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.

Digital Biomarkers Market Report Highlights:

• Cardiovascular and metabolic disorders (CVMD) had the highest revenue share of more than 20.0% in the therapeutic area segment in 2021 and is anticipated that it will continue to have a significant major presence given the rising prevalence of cardiovascular diseases among patient populations around the globe. On the other hand, due to COVID-19 and emerging new technologies, it is anticipated that during the forecast period, market revenue share for respiratory disorders will expand at the fastest rate

• Due to the growing use of diagnostic monitoring meant for clinical disease and daily living, diagnostic digital biomarkers had the largest revenue share in the clinical practice segment in 2021. Moreover, the fastest revenue growth is anticipated for monitoring digital biomarkers during the forecast period

• Wearable had a revenue share of more than 39.0% in the digital biomarker type segment in 2021, due to the release of new, cutting-edge wearable smart watches and other products. As a result of the extensive usage of smartphones, worldwide, it is anticipated that revenue share growth for mobile-based applications would happen at the fastest rate during the forecast period. Additionally, rising usage of new technologies, and sensors, would also confront intense competition during the forecast period

• Healthcare companies hold the largest, more than 50.0% market share within the end-use category, in 2021, as a result of the rising indications and demands for cost-effective clinical trial and product analysis strategies

• North America dominated the market in 2021 and generated more than 59.0% share of the total revenue, as a result of its well-established advanced healthcare infrastructure and large expenditure in R&D activities. Furthermore, Europe would see the fastest rate of growth during the forecast period

• By engaging in partnerships, acquisitions, mergers, and product launches, key companies also help the market to expand. For instance, in 2021, Med able collaborated with the digital biomarkers business Aural Analytics to measure distant speech patterns and monitor their well-being and stage of decline

Table of Contents

Chapter 1 Research Methodology & Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates and Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity Flow Approach
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources
• 1.9 Report Objectives

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Digital BiomarkersMarket Summary, 2021

Chapter 3 Digital Biomarkers Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Digital Biomarkers Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
    • 3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
    • 3.3.1.3 Expanding Therapeutic Area Application
    • 3.3.1.4 Increasing Investment in Decentralized Clinical Trials
  • 3.3.2 Market Restraints Analysis
    • 3.3.2.1 Concerns about Data Privacy
    • 3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
• 3.4 Digital Biomarkers Market Analysis Tools: Porter's Five Forces Analysis
  • 3.4.1 Supplier Power
  • 3.4.2 Buyer Power
  • 3.4.3 Threat Of Substitutes
  • 3.4.4 Threat Of New Entrants
  • 3.4.5 Competitive Rivalry
• 3.5 Pestel Analysis
  • 3.5.1 Political & Legal Landscape
  • 3.5.2 Social Landscape
  • 3.5.3 Technology Landscape
  • 3.5.4 Environmental Analysis
• 3.6 Regulatory Framework
• 3.7 Technology Overview
• 3.8 Pricing Analysis
• 3.9 Covid-19 Impact Analysis
  • 3.9.1 Current And Future Impact Analysis
  • 3.9.2 Impact Of Covid-19 On Market Players

Chapter 4 Competitive Landscape

• 4.1 Market participation categorization
• 4.2 Public Companies
  • 4.2.1 Company Market Position Analysis
  • 4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
• 4.3 Detailed list of market players

Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 - 2030 (USD Million)

• 5.1 Type Movement Analysis, 2021 & 2030
  • 5.1.1 Wearable
    • 5.1.1.1 Wearable Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 5.1.2 Mobile Based Applications
    • 5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 5.1.3 Sensors
    • 5.1.3.1 Sensors Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 5.1.4 Others
    • 5.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 - 2030 (USD Million)

• 6.1 Clinical Practice Movement Analysis, 2021 & 2030
  • 6.1.1 Diagnostic Digital Biomarkers
    • 6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 6.1.2 Monitoring Digital Biomarkers
    • 6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 6.1.3 Predictive and Prognostic Digital Biomarkers
    • 6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 6.1.4 Others
    • 6.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 - 2030 (USD Million)

• 7.1 Therapeutic Area Movement Analysis, 2021 & 2030
  • 7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
    • 7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 7.1.2 Respiratory Disorders
    • 7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 7.1.3 Psychiatric Disorders
    • 7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 7.1.4 Sleep & Movement Disease
    • 7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 7.1.5 Neurological Disorders
    • 7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 7.1.6 Musculoskeletal Disorders
    • 7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 7.1.7 Others
    • 7.1.7.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 - 2030 (USD Million)

• 8.1 End-Use Movement Analysis, 2021 & 2030
  • 8.1.1 Healthcare Companies
    • 8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 8.1.2 Healthcare Providers
    • 8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 - 2030 (Million)
  • 8.1.3 Payers
    • 8.1.3.1 Payers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 8.1.4 Others
    • 8.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 - 2030 (USD Million)

• 9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
• 9.2 North America
  • 9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.2.2 U.S.
    • 9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.2.3 Canada
    • 9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
• 9.3 Europe
  • 9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.3.2 U.K.
    • 9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.3.3 Germany
    • 9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.3.4 Netherlands
    • 9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.3.5 Italy
    • 9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.3.6 Switzerland
    • 9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
• 9.4 Asia Pacific
  • 9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4.2 Japan
    • 9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4.3 China
    • 9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4.4 Australia
    • 9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4.5 India
    • 9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4.6 South Korea
    • 9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
• 9.5 Latin America
  • 9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.5.2 Brazil
    • 9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.5.3 Mexico
    • 9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
• 9.6 MEA
  • 9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.6.2 South Africa
    • 9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.6.3 Israel
    • 9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 10 Company Profiles

• 10.1 ActiGraph LLC
  • 10.1.1 Company Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Benchmarking
  • 10.1.4 Strategic Initiatives
• 10.2 AliveCor Inc
  • 10.2.1 Company Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Benchmarking
  • 10.2.4 Strategic Initiatives
• 10.3 Koneksa
  • 10.3.1 Company Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Benchmarking
  • 10.3.4 Strategic Initiatives
• 10.4 Amgen Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Benchmarking
  • 10.4.4 Strategic Initiatives
• 10.5 Biogen Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Benchmarking
  • 10.5.4 Strategic Initiatives
• 10.6 Altoida Inc
  • 10.6.1 Company Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Benchmarking
  • 10.6.4 Strategic Initiatives
• 10.7 IXICO plc
  • 10.7.1 Company Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Benchmarking
  • 10.7.4 Strategic Initiatives
• 10.8 Adherium Limited
  • 10.8.1 Company Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Benchmarking
  • 10.8.4 Strategic Initiatives
• 10.9 Empatica Inc
  • 10.9.1 Company Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Benchmarking
  • 10.9.4 Strategic Initiatives
• 10.10 Huma
  • 10.10.1 Company Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Benchmarking
  • 10.10.4 Strategic Initiatives
• 10.11 VivoSense
  • 10.11.1 Company Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Benchmarking
  • 10.11.4 Strategic Initiatives
• 10.12 ResApp (Pfizer)
  • 10.12.1 Company Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Benchmarking
  • 10.12.4 Strategic Initiatives